Treating people in the early stages of diabetes-related eye disease may help slow the progression of the condition, but a new study also suggests that it can’t help prevent vision loss in the future.

SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Lucentis ® ...

Please provide your email address to receive an email when new articles are posted on . Mynampati and colleagues measured VEGF levels in 59 eyes of patients with diabetic retinopathy (DR) who had ...

A report in the December issue of the Archives of Ophthalmology shows that injecting the corticosteroid triamcinolone into the eye may slow the progression of diabetic retinopathy, a complication of ...

A four-year clinical study has found that while early treatment of diabetes-related eye disease using anti-vascular endothelial growth factor (anti-VEGF; aflibercept) slowed progression to severe ...

Many people with diabetes have the earliest stage of diabetic retinopathy, called mild nonproliferative diabetic retinopathy (NPDR), without even knowing it, according to the American Academy of ...

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic ...

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...

Two large NIH-funded clinical studies have shown promising results that laser photocoagulation therapy prevents vision loss in patients with diabetic retinopathy. Results of the Diabetic Retinopathy ...